Nonetheless, as ELISA kits for measuring serum TSP2 levels are now commercially available from various sources, further studies, preferably together with the measurements of these established HF markers, are clearly required to validate our current findings, as well as to assess the cost-effectiveness of using this novel biomarker for early HF risk stratification in type 2 diabetes. This evidence concerns the gene THBS2 and hydrops fetalis.